Safety

Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…

Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…

Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…

Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…

Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…

Synopsis: AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients. The trial studied the AbbVie drug…

KEYPOINTS: The FDA has granted orphan drug designation (ODD) to CT120 for the treatment of acute lymphoblastic leukemia, a novel chimeric antigen…

Synopsis: BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (Vosoritide) for Injection, indicated…

Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor  XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…

SUMMARY: The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive…